Azitra Inc. has announced promising safety data from its Phase 1b trial of ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial, which is 50% enrolled, involves six patients who have received ATR12-351. The drug has been generally safe and well-tolerated, with only mild to moderate symptoms observed at the application site. The trial remains blinded, and no severe adverse events have been reported. Azitra is scheduled to present further details on this trial, along with its Phase 1/2 trial for ATR04-484, at the BIO International Convention in Boston on June 17, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.